How Does Lamisil Work to Kill Fungal Infections?

Lamisil, the brand name for terbinafine, kills fungi by blocking a specific enzyme called squalene epoxidase that fungi need to build their cell membranes. Without this enzyme, two things happen at once: the fungal cell runs out of ergosterol, the structural molecule its membrane depends on, and it simultaneously accumulates toxic levels of squalene, a precursor that builds up with nowhere to go. This one-two punch is what makes terbinafine genuinely fungicidal rather than merely fungistatic, and it explains why the drug remains a first-line treatment for stubborn infections like toenail fungus and athlete’s foot decades after its introduction.

A Two-Pronged Attack on Fungal Cells

Most people think of antifungal drugs as simply poisoning the fungus, but terbinafine’s mechanism is more like sabotaging a construction project and simultaneously flooding the worksite with hazardous material. Fungal cells rely on ergosterol the way human cells rely on cholesterol: it sits in the cell membrane and keeps it stable, flexible, and functional. Squalene epoxidase is an enzyme that sits early in the production line for ergosterol. When terbinafine locks onto this enzyme, ergosterol production stalls, and the membrane gradually loses integrity.

But the ergosterol shortage alone would only slow fungal growth. What actually kills the cell is the squalene that piles up behind the blocked enzyme. With the production line jammed, squalene accumulates to levels that become directly toxic to the fungal cell. Research in yeast has confirmed that accumulated squalene is lipotoxic if the cell cannot efficiently store it away in lipid droplets, supporting the idea that squalene buildup is a key driver of terbinafine’s ability to kill fungi outright rather than just stalling them.¹ This dual mechanism, membrane starvation plus toxic overload, is why terbinafine is described as having “primarily fungicidal action against many fungi.”²

Why It Targets Fungi but Spares Human Cells

A reasonable worry is that if terbinafine blocks ergosterol production in fungi, it might also block cholesterol production in humans, since both pathways use squalene epoxidase. The short answer is that terbinafine binds the fungal version of the enzyme far more tightly than it binds the human version. In lab measurements, terbinafine inhibits fungal squalene epoxidase at concentrations roughly 2,000 times lower than what would be needed to inhibit the rat liver version of the same enzyme. The fungal enzyme gets locked up at around 30 nanomolar, while the mammalian enzyme requires about 77 micromolar, and the binding behavior is different too: the drug is a non-competitive inhibitor of the fungal enzyme but a competitive inhibitor of the mammalian one.² In practical terms, at the doses used to treat fungal infections, terbinafine has no measurable effect on cholesterol synthesis in the body.

This selectivity is not accidental. The three-dimensional shape of fungal squalene epoxidase differs enough from the mammalian version that terbinafine fits snugly into the fungal enzyme’s active site but has a much weaker grip on the human one. Molecular modeling studies have mapped this interaction at atomic resolution, identifying exactly which amino acid residues in the fungal enzyme create the binding pocket that terbinafine exploits.³ That structural difference is what makes it possible to wipe out a fungal colony growing in your toenail without disrupting lipid metabolism throughout the rest of your body.

Fungicidal Versus Fungistatic and Why It Matters

Not all antifungal drugs kill fungi. Many, including the azole class (fluconazole, itraconazole), primarily slow fungal growth and rely on the immune system to finish the job. Terbinafine tends to be genuinely fungicidal against dermatophytes, the group of fungi responsible for athlete’s foot, jock itch, ringworm, and nail infections. Head-to-head lab testing has shown that terbinafine’s fungicidal activity against dermatophytes kicks in rapidly, within about seven hours, while itraconazole’s fungicidal effect against the same organisms was much slower and weaker.⁴

This distinction matters most in places where the immune system has limited reach, like the nail bed. Nails have minimal blood supply and no active immune patrol, so a drug that merely slows fungal growth may not get the job done before it’s cleared from the tissue. A drug that outright kills the fungus at the concentrations present in the nail has a meaningful practical advantage. Against yeasts like Candida, the gap between terbinafine and azoles narrows; terbinafine’s minimum inhibitory concentrations are higher for yeasts than for dermatophytes, and the difference in fungicidal activity between the two drug classes is less dramatic for those organisms.⁴ This is why terbinafine is the go-to for dermatophyte infections but not necessarily for yeast-driven conditions like oral thrush.

How Lamisil Reaches and Stays in Infected Tissue

Terbinafine is highly lipophilic, meaning it dissolves easily in fats and tends to accumulate in fatty tissues, skin, and keratin-rich structures like nails and hair. After you swallow an oral dose, it absorbs well from the gut and begins showing up in nails within one to two weeks. What makes it unusual among antifungals is how long it lingers: its half-life in nail tissue ranges from about 24 to 156 days, and it has been detected in nails for more than 252 days after the last dose.⁵ That extreme persistence is why a standard course of oral terbinafine for toenail fungus is typically only 12 weeks: the drug keeps working in the nail long after you stop taking it, giving the healthy nail months to grow out while the antifungal activity continues.

This pharmacokinetic profile also explains why topical and oral forms of the drug serve different purposes. Topical terbinafine cream or solution works well for surface-level infections of the skin, where the drug can soak directly into the outermost layers. Nails are a different problem. The dorsal (top) layer of the nail plate is made of dense hard keratin that acts as a barrier to drug penetration from the outside. This is why topical antifungals alone tend to fail for nail infections: the drug simply cannot penetrate deeply enough. Oral terbinafine reaches the nail from the inside, delivered through the nail bed’s blood supply and then deposited into the growing nail plate.

How Well It Works in Practice

Terbinafine’s strongest clinical track record is in toenail fungus, or onychomycosis, one of the most common and frustrating fungal infections. In a randomized trial comparing oral terbinafine with itraconazole (another leading antifungal), terbinafine achieved a mycological cure rate of about 81% compared with 63% for itraconazole by the end of the study period.⁶ Long-term follow-up data tell a more sobering story, though. A five-year blinded prospective study found that about 42% of terbinafine-treated patients remained clinically cured at the end of follow-up without needing retreatment, compared with roughly 18% of those treated with itraconazole.⁷ Terbinafine clearly outperformed its competitor, but the fact that more than half of patients had some degree of relapse or reinfection over five years underlines how stubborn nail fungus can be.

For athlete’s foot (tinea pedis), the picture is brighter. Topical terbinafine works well regardless of the specific formulation, whether it is a cream applied for a week or a single-dose film-forming solution. A meta-analysis found high efficacy across different formulations, treatment durations, and application schedules, with terbinafine having a unique advantage over other topical antifungals in the shortness of treatment needed.⁸ A single application of a terbinafine 1% film-forming solution produced relapse and reinfection rates similar to those seen with seven days of cream use.⁹ That convenience factor matters: the less you have to remember, the more likely you are to actually complete the treatment.

Taste Disturbance and Other Side Effects

Oral terbinafine is generally well tolerated, and most people taking it for a standard 12-week course will experience nothing more than mild gastrointestinal discomfort or headache. But the side effect that catches people off guard is taste disturbance, or dysgeusia. Objective testing has confirmed what case reports describe: terbinafine can diminish or distort all four major taste qualities (sweet, sour, salty, and bitter), and the problem appears to be taste-specific rather than related to a loss of smell.¹⁰ For most people who develop it, taste returns after stopping the drug, but recovery can be slow. A reported case of a 72-year-old woman who developed severe dysgeusia with a persistent metallic taste, aversion to sweet foods, and significant weight loss showed only gradual and incomplete recovery over several months after stopping the medication.¹¹ Cases that extreme are uncommon, but they illustrate why it is worth knowing about this side effect before starting treatment.

The liver question comes up frequently. Many physicians order liver function tests before and during terbinafine therapy, and package inserts carry warnings about rare but serious liver injury. A critical appraisal of the evidence, however, found that there was no time point during treatment at which routine monitoring meaningfully caught problems before symptoms appeared. The authors of that review did not recommend routine liver function monitoring; instead, they advised that patients be told to stop the drug and seek medical attention if they develop symptoms of liver injury such as unusual fatigue, dark urine, or yellowing of the skin.¹² If your doctor does order blood work anyway, that is not unreasonable given the severity of the rare cases that do occur, but the evidence suggests that your own awareness of symptoms is more useful than periodic blood tests.

Drug Interactions Through a Liver Enzyme

Terbinafine is a strong inhibitor of a liver enzyme called CYP2D6, which is involved in breaking down a wide range of medications. This means that while you’re on oral terbinafine, drugs metabolized by CYP2D6 may linger in your system at higher-than-expected levels. The inhibition is potent: terbinafine blocks this enzyme at very low concentrations.¹³ Medications commonly affected include certain antidepressants, beta-blockers, and cough suppressants.

An interesting wrinkle is that people carry different genetic variants of CYP2D6, and terbinafine’s inhibitory strength varies depending on which variant you have. Testing across genetic variants showed weaker inhibition of certain less common forms of the enzyme (CYP2D6.2 and CYP2D6.10) compared with the most common form (CYP2D6.1).¹⁴ In practice, this means the interaction risk is not identical for everyone, though your doctor is unlikely to order genetic testing just to calibrate terbinafine interactions. The practical takeaway is straightforward: if you take oral terbinafine and are on other medications, your prescriber should review the list for CYP2D6-dependent drugs and adjust doses if needed. Topical terbinafine, which enters the bloodstream at negligible levels, does not raise these concerns.

Fungal Resistance to Terbinafine

For most of terbinafine’s history, resistance was not a serious clinical worry. Dermatophytes remained highly susceptible, and the drug’s potency against squalene epoxidase was overwhelming. That picture has started to shift. Among a large collection of over 2,000 Trichophyton clinical isolates tested in one study, about 1% showed reduced susceptibility to terbinafine. Every resistant isolate carried a point mutation in the gene encoding squalene epoxidase, with mutations clustered at four specific positions in the protein.¹⁵

A separate study focusing on Trichophyton mentagrophytes, a species that causes infections in both humans and animals, identified a specific amino acid substitution (leucine to phenylalanine at position 393) in all four of the resistant strains tested. These strains had terbinafine minimum inhibitory concentrations of 16 to 32 micrograms per milliliter, far above typical susceptible levels.¹⁶ Resistance rates are still low overall, but the emergence of these mutations, particularly in South Asia where terbinafine use is widespread for chronic dermatophytosis, has raised concern that increasing use could select for resistant strains over time. For now, a 1% resistance rate is manageable, but it explains why treatment failures occasionally occur even with proper adherence, and it underscores the value of confirming the diagnosis with a fungal culture before starting therapy when infections are recurrent or unresponsive.

Scalp Ringworm in Children

Terbinafine is not only used in adults. Tinea capitis, or fungal infection of the scalp, is one of the most common childhood fungal diseases, and it requires systemic (oral) treatment because topical drugs cannot reach the hair follicle effectively. For decades, griseofulvin was the standard treatment, but terbinafine has become a widely used alternative, especially when the causative organism is a Trichophyton species.

A meta-analysis of randomized trials found that a two- to four-week course of terbinafine was at least as effective as a six- to eight-week course of griseofulvin for Trichophyton scalp infections.¹⁷ A head-to-head trial found no significant difference in overall outcome between four weeks of terbinafine and eight weeks of griseofulvin, except in a subgroup of children with Trichophyton infections who weighed over 20 kilograms, where terbinafine cleared the infection faster.¹⁸ The shorter treatment course is a real advantage for families, since getting a child to take medication consistently for eight weeks is harder than doing so for two to four.

One caveat: when the causative fungus is Microsporum canis rather than a Trichophyton species, griseofulvin tends to perform better. This is why identifying the specific fungus matters in scalp infections. A quick culture result can steer treatment in the right direction and avoid a wasted course of the wrong drug.

How Potent Is Terbinafine Compared to Other Squalene Epoxidase Inhibitors

Terbinafine is not the only drug in its class. Naftifine, available as a topical cream, also inhibits squalene epoxidase, and earlier thiocarbamate compounds targeted the same enzyme. But terbinafine is by far the most potent of the group. Testing against squalene epoxidase from Trichophyton rubrum, the most common dermatophyte in humans, found that terbinafine had a 50% inhibitory concentration of just 15.8 nanomolar, making it the strongest inhibitor among all antifungals evaluated in that assay.¹⁹ That extreme potency at the enzyme level is part of what allows terbinafine to work in tissue compartments like nails, where drug concentrations are naturally lower than in the bloodstream. Even at the relatively modest levels that reach the nail bed, terbinafine is concentrated enough to exceed what is needed to kill dermatophytes, and the drug’s prolonged residence in keratin means those concentrations are sustained for months.